3 May 2017

Block Listing Application and Review

RNS Number : 0879E
Verona Pharma PLC
03 May 2017
 

Verona Pharma plc

 

("Verona Pharma" or the "Company")

 

Block Listing Application and Review

 

3 May 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, today announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 2,183,491 ordinary shares of £0.05 each to be admitted to trading on AIM as an extension of the block listing issued in respect of ordinary shares of £0.05 each (the "Ordinary Shares") which may arise pursuant to the exercise of warrants issued in connection with the placing completed in July 2016 (the "2016 Warrant Shares") as announced on 29 July 2016.

 

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its block listing facility (all figures relate to Ordinary Shares in the table below):

 

Name of company:

Verona Pharma plc

Name of scheme:

2016 Warrant Shares

Period of return:

From:

29/07/2016

To:

03/05/2017

Number and class of securities not issued/allotted under scheme(s) from previous return (following 50/1 share consolidation announced on 08/02/2017):

10,262,879

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2,183,491

Less:  Number of securities issued/allotted under scheme(s) during period:

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

12,446,370

Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission:

10,262,879 on 29/07/2016

Total number of shares in issue at the end of the period:

99,014,164

 

Name of contact:

Claire Poll

Telephone number of contact:

+44 (0)20 3283 4200

Date:

03/05/2017

 

-Ends-

 

For further information please contact:

 

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer




N+1 Singer

Tel: +44 (0)20 7496 3000

Aubrey Powell / James White/ Alex Laughton-Scott




FTI Consulting

Tel: +44 (0)20 3727 1000

Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins


 

Notes to Editors

 

About Verona Pharma plc

 

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

 

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRSSMFDDFWSELI

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us